Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.
Subscribe To Our Newsletter & Stay Updated
